Company Registration No. 15299935 (England and Wales)
Future Medicine Limited
Unaudited accounts
for the period from 21 November 2023 to 31 December 2024
Future Medicine Limited
Unaudited accounts
Contents
Future Medicine Limited
Company Information
for the period from 21 November 2023 to 31 December 2024
Directors
James Jean-Pierre Drake
Danny Alexander Al-Khafaji
Company Number
15299935 (England and Wales)
Registered Office
Future Medicine Ltd
1 Albert Place
London
London
N3 1QB
England
Future Medicine Limited
Statement of financial position
as at 31 December 2024
Cash at bank and in hand
49,257
Creditors: amounts falling due within one year
(411,755)
Net current liabilities
(300,494)
Called up share capital
100
Profit and loss account
(298,276)
Shareholders' funds
(298,176)
For the period ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 5 August 2025 and were signed on its behalf by
Danny Alexander Al-Khafaji
Director
Company Registration No. 15299935
Future Medicine Limited
Notes to the Accounts
for the period from 21 November 2023 to 31 December 2024
Future Medicine Limited is a private company, limited by shares, registered in England and Wales, registration number 15299935. The registered office is Future Medicine Ltd, 1 Albert Place, London, London, N3 1QB, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
25% Straight Line
Fixtures & fittings
25% Straight Line
The accounts have been prepared on the going concern basis which assumes the continued support of Mr James Drake, who is a director of the company.
4
Tangible fixed assets
Plant & machinery
Fixtures & fittings
Total
Cost or valuation
At cost
At cost
Additions
1,608
1,483
3,091
At 31 December 2024
1,608
1,483
3,091
Charge for the period
402
371
773
At 31 December 2024
402
371
773
At 31 December 2024
1,206
1,112
2,318
Future Medicine Limited
Notes to the Accounts
for the period from 21 November 2023 to 31 December 2024
Amounts falling due within one year
Amounts due from group undertakings etc.
44,482
6
Creditors: amounts falling due within one year
2024
Taxes and social security
3,948
Loans from directors
379,337
7
Transactions with related parties
Creditors as at 31 December 2024 include an amount of £379,337 payable to Mr James Drake who is a director of the company. Other debtors as at 31 December 2024 include amounts of £35,205 from Of Lost Time Limited and £9,277 from Drake Foundation, which is not-for profit company, where Mr James Drake is a director.
8
Average number of employees
During the period the average number of employees was 3.